Tafalgie therapeutics team’s

5 founders

Tafalgie Therapeutics was set up by an experienced and dynamic team with complementary scientific and business experiences.

Around its management team and founding partners, Tafalgie Therapeutics gathers a Scientific Committee and a Supervisory Board, but also federates a support team and a group of partners, all mobilized for the success of the project.

Eric schettini

President

Investor Biotech
Entrepreneur successful IPOs
25 years experience

stephane gaillard

General Manager

Pain research
Mice models
Characterization
Production

aziz moqrich

CSO

Specialist of the peripheral nervous system

Publication in international journals

olivier blin

Chairman of the COMEX

Professor of Clinical pharmacology (AMU)
Past positions: regulatory (ANMS)
Industrial (GSK)

laurent labatut

Chairman of the board
Chemical Industry Strategic positions in Marketing Management
Scale-Up

The Scientific Committee

The Scientific Committee, chaired by Aziz Moqrich, is a collegial advisory body and does not constitute a management body. Its mission is to advise the Chairman and other senior managers of the company in defining and implementing the company’s strategic orientations, to ensure the quality, legitimacy and consistency of its research and development activities and to monitor developments in science.

Honorary President

Ardem Patapoutian

Ardem Patapoutian is a molecular biologist specializing in sensory transduction.

His research has led to the identification of novel ion channels and receptors activated by temperature, mechanical force, and increased cell volume. His laboratory has shown that these ion channels play crucial roles in sensing temperature, touch, proprioception, pain, and regulating vascular tone.

Patapoutian was born in Lebanon in 1967 and attended the American University of Beirut for one year before he immigrated to The United States in 1986 and became a US citizen. He graduated from UCLA in 1990 and received his Ph.D. at Caltech in the lab of Dr. Barbara Wold in 1996.

After postdoctoral work with Dr. Lou Reichardt at UCSF, he joined the faculty of Scripps Research in 2000, where he is currently a Professor in the Department of Neuroscience. He also held a position at the Genomics Institute of The Novartis Research Foundation from 2000-2014.

Patapoutian was awarded the Young Investigator Award from the Society for Neuroscience in 2006 and was named an Investigator of the Howard Hughes Medical Institute in 2014.

He is a fellow of the American Association for the Advancement of Science (2016), a member of the National Academy of Sciences (2017) and a member of American Academy of Arts and Sciences (2020). He is a co-recipient of the 2017 Alden Spencer Award from Columbia (with David Ginty), the 2019 Rosenstiel Award for Distinguished Work in Basic Medical Research (with David Julius), the 2020 Kavli Prize in Neuroscience (with David Julius), the 2021 BBVA Foundation Frontiers of Knowledge Award (shared with David Julius), and the 2021 Nobel Prize in Physiology or Medicine (with David Julius).

2021 : Nobel Prize in Physiology or Medicine (with David Julius)

Jon Levine

Neuroscientist

Jon David Levine is an American neuroscientist known for his researches on pain and analgesia, particularly in the area of placebo studies. He is a professor of medicine, of oral and maxillofacial surgery, and of neurosciences at the University of California, San Francisco (UCSF).
 
Prof. Levine’s research focuses on pain and analgesia, such as the mechanism of the placebo effect in relieving pain. In 1978, he published an influential study showing that placebo analgesia could be blocked by the opioid antagonist naloxone.

Prof. Levine’s study represents the point where « placebo biology » was born.

Jean-Louis Kraus

Professor Emeritus at the University of Aix Marseille and former Professor at McGill University Montreal Canada

Jean-Louis Kraus is an emeritus professor at the University of Aix Marseille, france and a former Professor at the McGill University of Montreal Canada.
 
He has an extensive experience in the creation of biotechnology start-ups such as Trophos (which was acquired by Roche, Switzerland), BioPharmed and Planktovie. 
His international reputation in medicinal chemistry has led him to be a member of numerous scientific research evaluation committees (Inserm, FRM, Sidaction, ANRS) in France and abroad, as well as a senior scientist at Biochem Pharma (Canada. Moreover, he was a member of different advisory committees for strategic private investments and was in charge of the research & development at the Marseille University Council (Protisvalor creation).

Through his experience, Prof. Kraus has developed great networks during his career marked by commercial successes.

CLIFFORD WOOLF

DR. Clifford J. Woolf is professor of neurology and neurobiology at Harvard Medical School and Director of the F.M Kirby Neurobiology Center at Boston Children's Hospital. He has added greatly to the understanding of pain.

DR. CLIFFORD J. WOOLF was born in South Africa, where he earned his MB, BCh, and Ph.D. degrees. He then moved to London and became Professor of Neurobiology at University College London. In 1997 he was recruited by the Massachusetts General Hospital and Harvard Medical School to serve as the Richard J. Kitz Professor of Anesthesiology Research.

In 2010 he was named director of the F. M. Kirby Neurobiology Center at Boston Children’s Hospital and became Professor of Neurology and Neurobiology at HMS. He is faculty both in the department of Neurobiology at Harvard Medical School and in the Harvard Stem Cell Institute. Over his career, Dr. Woolf has received many honors and prizes.
In 2020 he was elected a fellow of the American Academy of Arts and Sciences and was awarded a Doctoris Honoris Causa from the University of Lausanne, Switzerland, he received a Gill Distinguished Scientist award and the Reeve-Irvine medal in 2017, and in 2015, the Kerr award from the American Pain Society.

Dr. Woolf was appointed to the Board of Scientific Councilors of the National Institute of Neurological Diseases and Stroke from 2015 to 2019 and is currently a member of the NIH HEAL Partnership Committee for the development of new treatments for pain and addiction. He has published over 300 research papers on molecular, cellular, and systems neurobiology and has more than 30 issued patents.

His research is devoted to investigating how the functional, chemical and stuctural plasticity of neurons is involved in both the normal adaptive functions of the nervous systems and in maladaptive changes that contribute to neurological diseases, with a particular focus on pain, regeneration and neurodegeneration and on the exploitation of stem celle derived neurons to model disease and for a drug screening.

Alain Eschalier

Professor Emeritus at the University of Aix Marseille and former Professor at McGill University Montreal Canada

Alain Eschalier (MD, PhD, PharmD) is an emeritus professor of Medical Pharmacology at the University of Clermont Auvergne, France and is board certified in pharmacology, psychiatry and human biology.
 
He is also the former head of the medical pharmacology department of the Faculty of Medicine and the University Hospital of Clermont-Ferrand.
 
Moreover, he was the founding director of the Inserm research units on the fundamental and clinical pharmacology of pain, participated in the creation of two start-up companies and was a consultant for several companies.
 
He chairs the Analgesia Institute since 2014, as well as the biomedical and public health research committee (CRBSP) and the scientific council of the French Society of Pharmacology and Therapeutics (SFPT) since 2015.

Prof. Eschalier is developing his research on the preclinical and clinical pharmacology of analgesics and the pathophysiology of chronic pain.

An EXPERT TEAM

Tafalgie Therapeutics has brought together a world-class team of scientists, engineers, legal and regulatory experts, financiers, operational managers…

laure lo ré

Scientist
Neuroscience – PHD

catarina santos

Scientist
Neuroscience – PHD

joanie delbano

Regulatory
Immunology Pharmacist

lucas Cortial

Expert
PHD Student Pharmaceutical Sciences

Caroline Mathon

General Secretary

emma schettini

CFO

Cyril Ducamin

COO

mathilde schettini

Communication

« If the pain represents a crucial contemporary issue, the aging of the population only reinforces the need for curative solutions in this field. The personalities that compose the Tafalgie Therapeutics team appeared to me to be passionate, ambitious and solid! ”

Laurent Labatut – Chairman on the board

Discover the key milestones in the progress of the Tafalgie project

Contact-us
for more information

JOIN-US

Follow-us to know the actuality

Click here